Pastorino U, et al. Blood microRNA and LDCT reduce unnecessary LDCT repeats in lung cancer screening: results of prospective BioMILD trial. Abstract PL02.04. WCLC 2019, 7-10 september, Barcelona, Spanje.
Pembrolizumab bij patiënten met NSCLC en performance status 2
mei 2020 | Immuuntherapie, Longoncologie